First Time Loading...

Reata Pharmaceuticals Inc
NASDAQ:RETA

Watchlist Manager
Reata Pharmaceuticals Inc Logo
Reata Pharmaceuticals Inc
NASDAQ:RETA
Watchlist
Price: 172.36 USD
Updated: May 15, 2024

Reata Pharmaceuticals Inc
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Reata Pharmaceuticals Inc
Gross Profit Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Reata Pharmaceuticals Inc
NASDAQ:RETA
Gross Profit
$21.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Gross Profit
$59.6B
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
2%
Bristol-Myers Squibb Co
NYSE:BMY
Gross Profit
$34.6B
CAGR 3-Years
2%
CAGR 5-Years
16%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Gross Profit
$38.8B
CAGR 3-Years
55%
CAGR 5-Years
N/A
CAGR 10-Years
-1%
Merck & Co Inc
NYSE:MRK
Gross Profit
$46B
CAGR 3-Years
17%
CAGR 5-Years
9%
CAGR 10-Years
6%
Eli Lilly and Co
NYSE:LLY
Gross Profit
$28.8B
CAGR 3-Years
14%
CAGR 5-Years
11%
CAGR 10-Years
5%

See Also

What is Reata Pharmaceuticals Inc's Gross Profit?
Gross Profit
21.9m USD

Based on the financial report for Jun 30, 2023, Reata Pharmaceuticals Inc's Gross Profit amounts to 21.9m USD.